- Home
- Publications
- Publication Search
- Publication Details
Title
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 11, Pages 2330-2339
Publisher
American Society of Hematology
Online
2012-06-21
DOI
10.1182/blood-2012-01-406108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Hyaluronan Facilitates Transforming Growth Factor-β1-dependent Proliferation via CD44 and Epidermal Growth Factor Receptor Interaction
- (2011) Soma Meran et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
- (2011) Sònia Tugues et al. MOLECULAR ASPECTS OF MEDICINE
- c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice
- (2011) Vivienne Olaku et al. MOLECULAR BIOLOGY OF THE CELL
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration
- (2011) Y Luo et al. ONCOGENE
- CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer
- (2011) Q. Zeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia
- (2010) K. Harhouri et al. BLOOD
- Clinical Application of Therapies Targeting VEGF
- (2010) George D. Yancopoulos CELL
- Bevacizumab: current updates in treatment
- (2010) Margaret EM Van Meter et al. CURRENT OPINION IN ONCOLOGY
- Gicerin/Cd146 is involved in zebrafish cardiovascular development and tumor angiogenesis
- (2010) Ju-Hoon So et al. GENES TO CELLS
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
- (2010) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis
- (2009) M. Tremmel et al. BLOOD
- Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization
- (2009) Chaogu Zheng et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
- (2009) Axel Grothey et al. Nature Reviews Clinical Oncology
- EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44
- (2008) Zsuzsanna Pályi-Krekk et al. CANCER LETTERS
- Generation and Characterization of a Panel of Monoclonal Antibodies Against Distinct Epitopes of Human CD146
- (2008) Ying Zhang et al. HYBRIDOMA
- Blockade of adhesion molecule CD146 causes pregnancy failure in mice
- (2008) Qin Liu et al. JOURNAL OF CELLULAR PHYSIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started